ReviewClinical and experimental gastroenterology2020
Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy.
Review in Clinical and experimental gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 46 citations in OpenAlex.
- Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial.Clinical drug investigation · 2023Trial
- A microbiota-IPA axis facilitates intestinal stem cell-mediated regeneration in colitis through a Hopx-associated program.Nature communications · 2026Article
- Microbiota-derived IPA protects against colitis by regulating intestinal HMGCS2-mediated ketogenesis to facilitate mucosal healing.Nature communications · 2026Article
- EngineeredFrontiers in immunology · 2026Article
- Analysis of the potential for immunosuppression of infants with in-utero and breast milk exposure to antitumor necrosis factor alpha agents: are all agents equally safe?International journal of women's dermatology · 2025Review
- Engineered Probiotic Saccharomyces boulardii Reduces Colitis-Associated Colorectal Cancer Burden in Mice.Digestive diseases and sciences · 2025Article
- A Rare Presentation of a Devastating Disease: Hepatosplenic T-Cell Lymphoma in Crohn's Disease Without Thiopurine Exposure.ACG case reports journal · 2025Article
- Pathogenetic Mechanisms Linking Sarcoidosis to Lymphoma.International journal of molecular sciences · 2025Review
- Ulcerative colitis: the healing power of macrophages.Tissue barriers · 2025Review
- Marginal Zone Lymphoma in a Case of Hidradenitis Suppurativa Treated With Adalimumab Therapy.Journal of community hospital internal medicine perspectives · 2025Article
- Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023.Intestinal research · 2024Article
- Article
- Refractory Hidradenitis Suppurativa: A Diagnosis to Consider.GE Portuguese journal of gastroenterology · 2024Article
- Not Everything That Ulcerates Is Crohn's Disease.GE Portuguese journal of gastroenterology · 2023Article
- Plasmablastic lymphoma occurring in ulcerative colitis during treatment with immunosuppressive therapy.Clinical journal of gastroenterology · 2023Article
- Death of tonsillar B cells by NETosis.Cell death discovery · 2023Article
- Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management.Cancers · 2023Review
- Article
- Emerging strategy towards mucosal healing in inflammatory bowel disease: what the future holds?Frontiers in immunology · 2023Review
- Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis.Journal of Cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-tumor necrosis factor alpha (ATA) therapy plays a significant role in the treatment of moderate to severe inflammatory bowel disease (IBD). There are concerns regarding risks associated with their use, including malignancy and, specifically, lymphoma. Many previous studies have sought to determine whether there is a true link between ATA therapy in IBD and development of lymphoma. However they have been hindered by short follow-up times, few cases, and confounding factors such as previous thiopurine exposure. This review seeks to update the literature by evaluating more recent studies assessing the link between ATA monotherapy and lymphoma development. It also summarizes findings of those studies and provides additional clinical guidance pertaining to this class of biologic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.